E Merck fuses French orthopaedic units:
This article was originally published in Clinica
Executive Summary
E Merck has merged two of its French companies, Prothaid and Impact, to create Merck Biomaterial France. The new company, which hopes to gain 14% of the French orthopaedic market this year, is expected to have an annual turnover of around Fr 160 million ($32.6 million). E Merck acquired Prothaid, specialising in ligament prostheses, last February (see Clinica No 643, p 11) and has now merged it with Impact, which produces joint prostheses. The German company invested Fr 80 million in a manufacturing plant in Valence, while commercial and marketing activities will continue to be carried out in Bordeaux, Levallois and Charnoz.
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.